Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS

Talking Therapeutics

Cost Effectiveness of SGLT2 Inhibitors in Question for Patients With HFpEF

05/19/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings explores findings from a study in which researchers evaluated the cost effectiveness of SGLT2 inhibitors for patients with heart failure with preserved ejection fraction (HFpEF).

Dr Jennings explores findings...

05/19/2023

Pharmacy Learning Network

Talking Therapeutics

A Striking Win for Statins

05/24/2024

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this installment of Talking Therapeutics, Dr Jennings explores a new paper outlining the potential benefit of statins on key outcomes in patients with heart failure with preserved ejection fraction (HFpEF).

In this installment of Talking...

05/24/2024

Pharmacy Learning Network

Talking Therapeutics

Heart Failure Treatment Insight From ACC.2021

05/19/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week's installment of Talking Therapeutics, Dr Jennings offers a breakdown on the latest heart failure therapy data, which was recently presented at the American College of Cardiology's annual meeting.

In this week's installment of...

05/19/2021

Pharmacy Learning Network

Talking Therapeutics

Full Steam Ahead for SGLT2 Inhibitors

03/02/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week's Talking Therapeutics column, Dr Jennings reviews new data on SGLT2 inhibitors for patients with heart failure with preserved ejection fraction.

In this week's Talking...

03/02/2022

Pharmacy Learning Network

Talking Therapeutics

New Data Emerges for Managing Type 2 Diabetes

10/06/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings explores research comparing the efficacy of several SGLT2 inhibitors as second-line therapy options for patients with type 2 diabetes who have been treated with metformin.

Dr Jennings explores research...

10/06/2022

Pharmacy Learning Network

Talking Therapeutics

A New Breakthrough In Anticoagulation

09/26/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

"Most patients with atrial fibrillation require life-long anticoagulation to prevent stroke, which exposes them to a significant cumulative risk for major hemorrhage, says Dr Jennings. "While most of the bleeding episodes that these patients...

"Most patients with atrial...

09/26/2023

Pharmacy Learning Network

Talking Therapeutics

Confirming Tenecteplase Over Alteplase for Acute Ischemic Stroke

02/23/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings reviews new data comparing thrombolytic treatment options for patients with acute ischemic stroke.

Dr Jennings reviews new data...

02/23/2023

Pharmacy Learning Network

Talking Therapeutics

Helping Pulmonary Artery Hypertension Patients Take a Breath

09/29/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week’s installment of Talking Therapeutics, we explore the pulmonary artery hypertension drug therapy landscape and highlight the findings from a seminal paper published recently.

In this week’s installment of...

09/29/2021

Pharmacy Learning Network

Talking Therapeutics

Taking the “Ouch” Out of Gout Attacks in Heart Failure

05/26/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings discusses new research on colchicine for gout flares and reminds fellow pharmacists to keep in mind appropriate dosing and potential drug interactions.

Dr Jennings discusses new...

05/26/2022

Pharmacy Learning Network

Talking Therapeutics

End of 2022 Wrap Up: SGLT2 Inhibitors, COVID-19 Treatments and Boosters

12/28/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In his final column of the year, Dr Jennings revisits the most pertinent stories from 2022, emphasizing the efficacy of SGLT2 inhibitors for patients with heart failure as well as the continuously changing landscape of COVID-19 treatments.

In his final column of the year,...

12/28/2022

Pharmacy Learning Network